The latest price target for Gilead Sciences (NASDAQ: GILD) was reported by B of A Securities on September 8, 2023. The analyst firm set a price target for $95.00 expecting GILD to rise to within 12 months (a possible 25.78% upside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Gilead Sciences (NASDAQ: GILD) was provided by B of A Securities, and Gilead Sciences upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gilead Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gilead Sciences was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.

While ratings are subjective and will change, the latest Gilead Sciences (GILD) rating was a upgraded with a price target of $88.00 to $95.00. The current price Gilead Sciences (GILD) is trading at is $75.53, which is out of the analyst’s predicted range.

The latest price target for Gilead Sciences (NASDAQ: GILD) was reported by B of A Securities on September 8, 2023. The analyst firm set a price target for $95.00 expecting GILD to rise to within 12 months (a possible 25.78% upside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Gilead Sciences (NASDAQ: GILD) was provided by B of A Securities, and Gilead Sciences upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gilead Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gilead Sciences was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.

While ratings are subjective and will change, the latest Gilead Sciences (GILD) rating was a upgraded with a price target of $88.00 to $95.00. The current price Gilead Sciences (GILD) is trading at is $75.53, which is out of the analyst’s predicted range.

The latest price target for Gilead Sciences (NASDAQ: GILD) was reported by B of A Securities on September 8, 2023. The analyst firm set a price target for $95.00 expecting GILD to rise to within 12 months (a possible 25.78% upside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Gilead Sciences (NASDAQ: GILD) was provided by B of A Securities, and Gilead Sciences upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gilead Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gilead Sciences was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.

While ratings are subjective and will change, the latest Gilead Sciences (GILD) rating was a upgraded with a price target of $88.00 to $95.00. The current price Gilead Sciences (GILD) is trading at is $75.53, which is out of the analyst’s predicted range.

The latest price target for Gilead Sciences (NASDAQ: GILD) was reported by B of A Securities on September 8, 2023. The analyst firm set a price target for $95.00 expecting GILD to rise to within 12 months (a possible 25.78% upside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Gilead Sciences (NASDAQ: GILD) was provided by B of A Securities, and Gilead Sciences upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gilead Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gilead Sciences was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.

While ratings are subjective and will change, the latest Gilead Sciences (GILD) rating was a upgraded with a price target of $88.00 to $95.00. The current price Gilead Sciences (GILD) is trading at is $75.53, which is out of the analyst’s predicted range.

The latest price target for Gilead Sciences (NASDAQ: GILD) was reported by B of A Securities on September 8, 2023. The analyst firm set a price target for $95.00 expecting GILD to rise to within 12 months (a possible 25.78% upside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Gilead Sciences (NASDAQ: GILD) was provided by B of A Securities, and Gilead Sciences upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gilead Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gilead Sciences was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.

While ratings are subjective and will change, the latest Gilead Sciences (GILD) rating was a upgraded with a price target of $88.00 to $95.00. The current price Gilead Sciences (GILD) is trading at is $75.53, which is out of the analyst’s predicted range.

The latest price target for Gilead Sciences (NASDAQ: GILD) was reported by B of A Securities on September 8, 2023. The analyst firm set a price target for $95.00 expecting GILD to rise to within 12 months (a possible 25.78% upside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Gilead Sciences (NASDAQ: GILD) was provided by B of A Securities, and Gilead Sciences upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gilead Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gilead Sciences was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.

While ratings are subjective and will change, the latest Gilead Sciences (GILD) rating was a upgraded with a price target of $88.00 to $95.00. The current price Gilead Sciences (GILD) is trading at is $75.53, which is out of the analyst’s predicted range.

The latest price target for Gilead Sciences (NASDAQ: GILD) was reported by B of A Securities on September 8, 2023. The analyst firm set a price target for $95.00 expecting GILD to rise to within 12 months (a possible 25.78% upside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Gilead Sciences (NASDAQ: GILD) was provided by B of A Securities, and Gilead Sciences upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gilead Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gilead Sciences was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.

While ratings are subjective and will change, the latest Gilead Sciences (GILD) rating was a upgraded with a price target of $88.00 to $95.00. The current price Gilead Sciences (GILD) is trading at is $75.53, which is out of the analyst’s predicted range.

The latest price target for Gilead Sciences (NASDAQ: GILD) was reported by B of A Securities on September 8, 2023. The analyst firm set a price target for $95.00 expecting GILD to rise to within 12 months (a possible 25.78% upside). 43 analyst firms have reported ratings in the last year.

The latest analyst rating for Gilead Sciences (NASDAQ: GILD) was provided by B of A Securities, and Gilead Sciences upgraded their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gilead Sciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gilead Sciences was filed on September 8, 2023 so you should expect the next rating to be made available sometime around September 8, 2024.

While ratings are subjective and will change, the latest Gilead Sciences (GILD) rating was a upgraded with a price target of $88.00 to $95.00. The current price Gilead Sciences (GILD) is trading at is $75.53, which is out of the analyst’s predicted range.